Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Cancer crawled date : 2021 - 06 - 04 save search
Guardant Health Presents Data at 2021 ASCO Annual Meeting Showing Blood Test Highly Accurate in Detecting Colorectal Cancer in Patients With Early-Stage Cancer
Published: 2021-06-04 (Crawled : 20:00) - biospace.com/
GH | News 4 | $18.1 4.38% 4.2% 1.6M
|
Health Services
|
| O: 0.0%
H: 2.56%
C: -0.18%
blood test cancer colorectal cancer
Sorrento Announces Positive Results From Its License Partner, Kelun, on a Phase I Study of Safety and Pharmacokinetics of A166, a Novel HER2 ADC for Advanced HER2 Positive Breast Cancers
Published: 2021-06-04 (Crawled : 20:00) - globenewswire.com
SRNE | $0.015 -8.85% 56K
|
Health Technology
| Email alert
Add to watchlist
positive results positive results cancer license breast cancer her2+ her2- her2
New Drug Effective Against Lung Cancers Caused by Common Genetic Error
Published: 2021-06-04 (Crawled : 19:00) - prnewswire.com
AMGN | News | $273.085 -0.17% -0.17% 2.5M
|
Health Technology
| Email alert
Add to watchlist
new drug genetic lung cancer cancer drug
Sorrento and Researchers at Karolinska Institutet Have Signed a Research Collaboration Agreement on iPSC-Derived Dimeric Antigen Receptor-Modified Natural Killer (DAR-NK) Cells With The Vision to Bring “Off-The-Shelf" NK Cell-Based Cancer Treatments Rapidly to Patients
Published: 2021-06-04 (Crawled : 18:00) - globenewswire.com
SRNE | $0.015 -8.85% 56K
|
Health Technology
|
| O: 1.73%
H: 2.43%
C: -1.58%
treatment collaboration cancer research
Merus Presents Clinical Data on Zenocutuzumab in NRG1-fusion (NRG1+) Cancers at the American Society of Clinical Oncology (ASCO) 2021 Annual Meeting (Oral Abstract)
Published: 2021-06-04 (Crawled : 17:00) - globenewswire.com
MRUS | $41.96 2.79% 2.72% 740K
|
Health Technology
|
| O: 0.2%
H: 14.22%
C: 3.19%
cancer
Novartis investigational checkpoint inhibitor tislelizumab met primary endpoint of overall survival in pivotal Phase III trial of esophageal cancer after systemic therapy
Published: 2021-06-04 (Crawled : 13:15) - prnewswire.com
NVS | News | $98.35 1.1% 0.0% 2.2M
|
Health Technology
|
| O: 0.55%
H: 0.41%
C: 0.0%
therapy cancer trial
G1 Therapeutics Presents Data on COSELA™ (trilaciclib) at ASCO on Potential Immune Activation in Patients with Newly Diagnosed Extensive-Stage Small Cell Lung Cancer
Published: 2021-06-04 (Crawled : 13:15) - globenewswire.com
GTHX | $3.98 -5.01% -5.28% 340K
|
Health Technology
|
| O: 0.47%
H: 0.42%
C: -1.04%
lung cancer potential cancer trilaciclib
G1 Therapeutics Presents Phase 1 Data at ASCO Describing Favorable Safety Profile and Evidence of Antitumor Activity of Rintodestrant Combined with Palbociclib in Patients with ER+/HER2- Advanced Breast Cancer
Published: 2021-06-04 (Crawled : 13:15) - globenewswire.com
GTHX | $3.98 -5.01% -5.28% 340K
|
Health Technology
|
| O: 0.47%
H: 0.42%
C: -1.04%
phase 1 cancer breast cancer phase 3 her2+ her2- her2
A Phase 1 Study of RTX-321, an Engineered Red Blood Cell as an Artificial Antigen-Presenting Cell Expressing HLA-A*02 with the HPV-16 E7 Peptide and 4-1BB Ligand with Membrane-Bound IL-12 for the Treatment of HPV 16-Positive Cancers
Published: 2021-06-04 (Crawled : 13:00) - rubiustx.com
RUBY | $0.057 -99.3% 760K
|
Health Technology
|
| O: 0.62%
H: 3.05%
C: 1.94%
treatment blood phase 1 positive rtx-321 cancer phase 3
Cell-Free DNA Guided Targeted Therapy Leads to Better Survival in Advanced Non-Small Cell Lung Cancer
Published: 2021-06-04 (Crawled : 13:00) - biospace.com/
A | $137.49 -1.23% -0.36% 1.6M
|
Health Technology
|
| O: 0.98%
H: 0.51%
C: 0.15%
lung cancer therapy cancer
Biodesix Partners with Datavant to Enhance Value of Lung Cancer Databank
Published: 2021-06-04 (Crawled : 12:00) - biospace.com/
BDSX | $1.26 -1.56% -1.59% 7.1K
|
Health Services
|
| O: 2.63%
H: 0.0%
C: -8.23%
lung cancer cancer
Sanofi partnering with leading academic cooperative groups to study amcenestrant in the adjuvant setting for patients with estrogen receptor positive breast cancer
Published: 2021-06-04 (Crawled : 12:00) - biospace.com/
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: 0.79%
H: 0.55%
C: 0.19%
positive cancer breast cancer
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.